The DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.
Atrial shunt device for heart failure with preserved and mildly reduced ejection fraction (REDUCE LAP-HF II): a randomised, multicentre, blinded, sham-controlled trial
Open accessAbstract
BACKGROUND Placement of an interatrial shunt device reduces pulmonary capillary wedge pressure during exercise in patients with heart failure and preserved or mildly reduced ejection fraction. We aimed to investigate whether an interatrial shunt can reduce heart failure events or improve health status in these patients. METHODS In this randomised, international, blinded, sham-controlled trial performed at 89 health-care centres, we included patients (aged ≥40 years) with symptomatic heart failure, an ejection fraction of at least 40%, and pulmonary capillary wedge pressure during exercise of at least 25 mm Hg while exceeding right atrial pressure by at least 5 mm Hg. Patients were randomly assigned (1:1) to receive either a shunt device or sham procedure. Patients and outcome assessors were masked to randomisation. The primary endpoint was a hierarchical composite of cardiovascular death or non-fatal ischemic stroke at 12 months, rate of total heart failure events up to 24 months, and change in Kansas City Cardiomyopathy Questionnaire overall summary score at 12 months. Pre-specified subgroup analyses were conducted for the heart failure event endpoint. Analysis of the primary endpoint, all other efficacy endpoints, and safety endpoints was conducted in the modified intention-to-treat population, defined as all patients randomly allocated to receive treatment, excluding those found to be ineligible after randomisation and therefore not treated. This study is registered with ClinicalTrials.gov, NCT03088033. FINDINGS Between May 25, 2017, and July 24, 2020, 1072 participants were enrolled, of whom 626 were randomly assigned to either the atrial shunt device (n=314) or sham procedure (n=312). There were no differences between groups in the primary composite endpoint (win ratio 1·0 [95% CI 0·8-1·2]; p=0·85) or in the individual components of the primary endpoint. The prespecified subgroups demonstrating a differential effect of atrial shunt device treatment on heart failure events were pulmonary artery systolic pressure at 20W of exercise (pinteraction=0·002 [>70 mm Hg associated with worse outcomes]), right atrial volume index (pinteraction=0·012 [≥29·7 mL/m2, worse outcomes]), and sex (pinteraction=0·02 [men, worse outcomes]). There were no differences in the composite safety endpoint between the two groups (n=116 [38%] for shunt device vs n=97 [31%] for sham procedure; p=0·11). INTERPRETATION Placement of an atrial shunt device did not reduce the total rate of heart failure events or improve health status in the overall population of patients with heart failure and ejection fraction of greater than or equal to 40%. FUNDING Corvia Medical.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Empagliflozin in heart failure with a preserved ejection fraction
Anker, S. D., Butler, J., Filippatos, G., Ferreira, J. P., Bocchi, E., Böhm, M., Brunner–La Rocca, H.-P., Choi, D.-J., Chopra, V., Chuquiure-Valenzuela, E., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2107038 · Cited by 4,874
Angiotensin–Neprilysin Inhibition in Heart Failure with Preserved Ejection Fraction
Solomon, S. D., McMurray, J. J. V., Anand, I. S., Ge, J., Lam, C. S. P., Maggioni, A. P., Martinez, F., Packer, M., Pfeffer, M. A., Pieske, B., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1908655 · Cited by 2,430
Self-citationPhenotype-Specific Treatment of Heart Failure With Preserved Ejection Fraction: A Multiorgan Roadmap
Shah, S. J., Kitzman, D. W., Borlaug, B. A., van Heerebeek, L., Zile, M. R., Kass, D. A., & Paulus, W. J. (2016) · Circulation · doi:10.1161/circulationaha.116.021884 · Cited by 1,003
Self-citationNassif, M. E., Windsor, S. L., Borlaug, B. A., Kitzman, D. W., Shah, S. J., Tang, F., Khariton, Y., Malik, A. O., Khumri, T., Umpierrez, G., et al. (2021) · Nature Medicine · doi:10.1038/s41591-021-01536-x · Cited by 618
Self-citationShah, S. J., Borlaug, B. A., Kitzman, D. W., McCulloch, A. D., Blaxall, B. C., Agarwal, R., Chirinos, J. A., Collins, S., Deo, R. C., Gladwin, M. T., et al. (2020) · Circulation · doi:10.1161/circulationaha.119.041886 · Cited by 436
Cited by
2022 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension
Humbert, M., Kovacs, G., Hoeper, M. M., Badagliacca, R., Berger, R. M. F., Brida, M., Carlsen, J., Coats, A. J. S., Escribano-Subias, P., Ferrari, P., et al. (2022) · European Heart Journal · doi:10.1093/eurheartj/ehac237 · Cited by 3,975
Self-citation2022 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension
Humbert, M., Kovacs, G., Hoeper, M. M., Badagliacca, R., Berger, R. M. F., Brida, M., Carlsen, J., Coats, A. J. S., Escribano-Subias, P., Ferrari, P., et al. (2023) · European Respiratory Journal · doi:10.1183/13993003.00879-2022 · Cited by 2,247
Heart Failure With Preserved Ejection Fraction
Borlaug, B. A., Sharma, K., Shah, S. J., & Ho, J. E. (2023) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2023.01.049 · Cited by 742
Self-citationKittleson, M. M., Panjrath, G. S., Amancherla, K., Davis, L. L., Deswal, A., Dixon, D. L., Januzzi, J. L., & Yancy, C. W. (2023) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2023.03.393 · Cited by 554
Metadata
- Authors
- Shah, S. J., Borlaug, B. A., Chung, E. S., Cutlip, D. E., Debonnaire, P., Fail, P. S., Gao, Q., Hasenfuß, G., Kahwash, R., Kaye, D. M., Litwin, S. E., Lurz, P., Massaro, J. M., Mohan, R. C., Ricciardi, M. J., Solomon, S. D., Sverdlov, A. L., Swarup, V., van Veldhuisen, D. J., Winkler, S., Leon, M. B., Akar, J., Ando, J., Anzai, T., Asakura, M., Bailey, S., Basuray, A., Bauer, F., Bergmann, M., Blair, J., Cavendish, J., Chung, E., Cikes, M., Dauber, I., Donal, E., Eicher, J.-C., Fail, P., Flaherty, J., Freixa, X., Gafoor, S., Gertz, Z., Gordon, R., Guazzi, M., Guerrero-Miranda, C., Gupta, D., Gustafsson, F., Hadadi, C., Hakemi, E., Handoko, L., Hass, M., Hausleiter, J., Hayward, C., Hickey, G., Hummel, S., Hussain, I., Isnard, R., Izumi, C., Jondeau, G., Juneman, E., Kinugawa, K., Kipperman, R., Krakowiak, B., Krim, S., Larned, J., Lewis, G., Lipsic, E., Magalski, A., Mazimba, S., Mazurek, J., McGrady, M., Mckenzie, S., Mehta, S., Mignone, J., Morsli, H., Nair, A., Noel, T., Orford, J., Parikh, K., Patterson, T., Penicka, M., Petrie, M., Pieske, B., Post, M., Raake, P., Romero, A., Ryan, J., Saito, Y., Sakamoto, T., Sakata, Y., Samara, M., Satya, K., Sindone, A., Starling, R., Trochu, J.-N., Upadhya, B., van der Heyden, J., van Empel, V., Varma, A., Vest, A., Wengenmayer, T., Westenfeld, R., Westermann, D., Yamamoto, K., & Zirlik, A.
- Venue
- The Lancet
- Publisher
- Elsevier BV
- Published
- 2022-03
- Volume
- 399
- Issue
- 10330
- Pages
- 1130-1140
- ISSN
- 0099-5355 (ISSN-L)
- 0140-6736
- OpenAlex
- W4210501450
- Cited by
- 249
- References
- 5
- FWCI
- 34.52
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Atrial shunt device for heart failure with preserved and mildly reduced ejection fraction (REDUCE LAP-HF II): a randomised, multicentre, blinded, sham-controlled trial. https://app.cochat.ai/papers/10.1016/s0140-6736(22)00016-2
- The paper
- Shah, S. J., Borlaug, B. A., Chung, E. S., Cutlip, D. E., Debonnaire, P., Fail, P. S., Gao, Q., Hasenfuß, G., Kahwash, R., Kaye, D. M., Litwin, S. E., Lurz, P., Massaro, J. M., Mohan, R. C., Ricciardi, M. J., Solomon, S. D., Sverdlov, A. L., Swarup, V., van Veldhuisen, D. J., . . . Zirlik, A. (2022). Atrial shunt device for heart failure with preserved and mildly reduced ejection fraction (REDUCE LAP-HF II): a randomised, multicentre, blinded, sham-controlled trial. The Lancet. https://doi.org/10.1016/s0140-6736(22)00016-2
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.